Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
‘We Are Here To Stay’ US Firm Says Of Biosimilar Ambitions
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
